Claire Falandry

ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

Jonathan A. Ledermann, Xavier Matías‐Guiu, Frédéric Amant et al. · Annals of Oncology · 2024 · 284 citations · Full text

Medicine, Oncology, Pathology +16

Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)

Michele Ghielmini, Kaspar Rufibach, Gilles Salles et al. · Annals of Oncology · 2005 · 161 citations · Full text

Medicine, Immunology, Oncology +8

Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Chemoresistant and Recurrent Advanced Epithelial Ovarian Cancer: Prospective Study of 81 Patients

Eddy Cotte, Olivier Gléhen, Faheez Mohamed et al. · World Journal of Surgery · 2007 · 148 citations

Medicine, Oncology, Surgery +16

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial

Claire Falandry, B. Weber, Aude-Marie Savoye et al. · Annals of Oncology · 2013 · 119 citations

Medicine, Gynecology, Oncology +13